Vor Biopharma Inc (VOR) FinancialsVORFinancialVor Biopharma Inc

In the context of the broader market, VOR competes directly with industry leaders such as MGTX and JBIO. With a market capitalization of $1.39B, it holds a significant position in the sector. When comparing efficiency, VOR's gross margin of N/A stands against MGTX's 97.77% and JBIO's N/A. Such benchmarking helps identify whether Vor Biopharma Inc. is trading at a premium or discount relative to its financial performance.

Vor Biopharma has shown a significant reduction in R&D expenses from $261.5 million in Q2 2025 to $25.9 million in Q2 2026, indicating improved cost management. However, the company reported a net loss of $62.81 million in Q2 2026, which raises concerns about its profitability.